Results for the follow-up of the RESPONSE study
Patient and physician perceptions on the symptomatic and economic burden of MPNs
Interim results of pegylated interferon alpha-2a for polycythemia vera and essential thrombocythemia
Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera
What is the unmet medical need of patients with PV and ET?
Haifa Kathrin Al-Ali